Could a common diabetes pill slow lung cancer?
NCT ID NCT07272057
First seen Jan 11, 2026 · Last updated May 21, 2026 · Updated 23 times
Summary
This study looks at whether adding an SGLT2 inhibitor (a diabetes drug) to standard cancer treatment can help people with both advanced lung cancer and type 2 diabetes live longer or keep their cancer from growing. About 200 adults will take either the SGLT2 inhibitor or other diabetes medicines, and researchers will track survival, heart problems, and side effects. The goal is to see if this drug offers extra benefits beyond controlling blood sugar.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.